{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:24:22Z","timestamp":1787963062962,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ghir.2022.101502","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T03:18:49Z","timestamp":1662693529000},"page":"101502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study"],"prefix":"10.1016","volume":"67","author":[{"given":"Elif Tutku","family":"Durmu\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl","family":"Atmaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Mete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerim","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Fidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramis","family":"\u00c7olak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu\u011fra","family":"Durmu\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ghir.2022.101502_bb0005","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.ghir.2022.101502_bb0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2022.101502_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary."},{"issue":"2","key":"10.1016\/j.ghir.2022.101502_bb0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine."},{"issue":"4","key":"10.1016\/j.ghir.2022.101502_bb0025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary."},{"issue":"2","key":"10.1016\/j.ghir.2022.101502_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary."},{"issue":"4","key":"10.1016\/j.ghir.2022.101502_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary."},{"issue":"4","key":"10.1016\/j.ghir.2022.101502_bb0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4158\/EP-2018-0500","article-title":"Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline","volume":"25","author":"Ezzat","year":"2019","journal-title":"Endocr. Pract."},{"issue":"1","key":"10.1016\/j.ghir.2022.101502_bb0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin. Endocrinol."},{"issue":"11","key":"10.1016\/j.ghir.2022.101502_bb0050","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.ghir.2022.101502_bb0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2022.101502_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig","year":"2015","journal-title":"Clin. Endocrinol."},{"issue":"7","key":"10.1016\/j.ghir.2022.101502_bb0065","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2022.101502_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary."},{"issue":"9","key":"10.1016\/j.ghir.2022.101502_bb0075","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ghir.2022.101502_bb0080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of growth hormone\u2013producing and non\u2013growth hormone\u2013producing pituitary adenomas: imaging characteristics and pathologic correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology."},{"issue":"4","key":"10.1016\/j.ghir.2022.101502_bb0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00004728-199207000-00004","article-title":"Volume of pituitary macroadenomas: assessment by MRI","volume":"16","author":"Lundin","year":"1992","journal-title":"J. Comput. Assist. Tomogr."},{"issue":"4","key":"10.1016\/j.ghir.2022.101502_bb0090","first-page":"610","article-title":"Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings","volume":"33","author":"Knosp","year":"1993","journal-title":"Neurosurgery."},{"key":"10.1016\/j.ghir.2022.101502_bb0095","series-title":"Clinical Management of Pituitary Disorders. Seminars in Neurological Surgery","first-page":"209","article-title":"Acromegaly: surgical treatment by transsphenoidal microsurgical removal of the pituitary adenoma","author":"Hardy","year":"1979"},{"issue":"7","key":"10.1016\/j.ghir.2022.101502_bb0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas\u2014diagnosis and emerging treatments","volume":"10","author":"Di Ieva","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.ghir.2022.101502_bb0105","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3390\/jcm11092464","article-title":"Classifying pituitary adenoma invasiveness based on radiological, surgical and histological features: a retrospective assessment of 903 cases","volume":"11","author":"Lu","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ghir.2022.101502_bb0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr. Pathol."},{"issue":"4","key":"10.1016\/j.ghir.2022.101502_bb0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1750-3639.2012.00599.x","article-title":"Clinicopathological correlations in pituitary adenomas","volume":"22","author":"Mete","year":"2012","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ghir.2022.101502_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2020.10.004","article-title":"Cytokeratin profiles in pituitary neuroendocrine tumors","volume":"107","author":"Asa","year":"2021","journal-title":"Hum. Pathol."},{"issue":"8","key":"10.1016\/j.ghir.2022.101502_bb0125","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.ghir.2022.101502_bb0130","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1210\/jc.2001-012012","article-title":"Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size","volume":"87","author":"Bevan","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.ghir.2022.101502_bb0135","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","article-title":"Somatostatin analogs in acromegaly","volume":"87","author":"Freda","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2022.101502_bb0140","article-title":"GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil","volume":"1-9","author":"Manosso","year":"2021","journal-title":"Endocrine."},{"key":"10.1016\/j.ghir.2022.101502_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101354","article-title":"Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: a hospital-based study of 237 cases","volume":"55","author":"Shen","year":"2020","journal-title":"Growth Hormon. IGF Res."},{"issue":"5","key":"10.1016\/j.ghir.2022.101502_bb0150","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/cen.12207","article-title":"Control of growth hormone and IGF 1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists","volume":"79","author":"Howlett","year":"2013","journal-title":"Clin. Endocrinol."},{"issue":"11","key":"10.1016\/j.ghir.2022.101502_bb0155","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.ghir.2022.101502_bb0160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-18-0254","article-title":"MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis","volume":"180","author":"Bonneville","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"10.1016\/j.ghir.2022.101502_bb0165","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ghir.2022.101502_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2022.101502_bb0175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO classification of pituitary tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr. Pathol."},{"issue":"7","key":"10.1016\/j.ghir.2022.101502_bb0180","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ghir.2022.101502_bb0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur. J. Endocrinol."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637422000594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637422000594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:52:50Z","timestamp":1761087170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637422000594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S1096637422000594"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2022.101502","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2022.101502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101502"}}